- Home
- AMRN vs OLMA Comparison
AMRN vs OLMA Comparison
Compare AMRN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- OLMA
- Stock Information
- Founded
- AMRN 1989
- OLMA 2006
- Country
- AMRN Ireland
- OLMA United States
- Employees
- AMRN N/A
- OLMA N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- OLMA Health Care
- Exchange
- AMRN Nasdaq
- OLMA Nasdaq
- Market Cap
- AMRN 317.1M
- OLMA 378.9M
- IPO Year
- AMRN 1993
- OLMA 2020
- Fundamental
- Price
- AMRN $14.87
- OLMA $8.02
- Analyst Decision
- AMRN Strong Sell
- OLMA Strong Buy
- Analyst Count
- AMRN 1
- OLMA 5
- Target Price
- AMRN $12.00
- OLMA $24.00
- AVG Volume (30 Days)
- AMRN 49.5K
- OLMA 1.1M
- Earning Date
- AMRN 10-29-2025
- OLMA 11-11-2025
- Dividend Yield
- AMRN N/A
- OLMA N/A
- EPS Growth
- AMRN N/A
- OLMA N/A
- EPS
- AMRN N/A
- OLMA N/A
- Revenue
- AMRN $219,361,000.00
- OLMA N/A
- Revenue This Year
- AMRN N/A
- OLMA N/A
- Revenue Next Year
- AMRN N/A
- OLMA N/A
- P/E Ratio
- AMRN N/A
- OLMA N/A
- Revenue Growth
- AMRN N/A
- OLMA N/A
- 52 Week Low
- AMRN $7.08
- OLMA $2.86
- 52 Week High
- AMRN $17.49
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- AMRN 45.45
- OLMA 66.94
- Support Level
- AMRN $14.54
- OLMA $7.66
- Resistance Level
- AMRN $15.46
- OLMA $8.40
- Average True Range (ATR)
- AMRN 0.47
- OLMA 0.67
- MACD
- AMRN -0.05
- OLMA 0.06
- Stochastic Oscillator
- AMRN 27.80
- OLMA 83.86
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.